Pharmacodynamics of morphine-induced neuronal nitric oxide production and antinociceptive tolerance development.
Elevated nitric oxide (NO) production has been implicated in the development of morphine antinociceptive tolerance. This study was conducted to establish the temporal relationship between morphine-induced increases in neuronal NO and loss of pharmacologic activity. Five groups of rats equipped with microdialysis probes in the jugular vein and hippocampus received an intravenous infusion of saline or morphine (0.3, 1, 2, or 3 mg/kg/h) for 8 h. Morphine concentrations in the blood and hippocampal microdialysate were determined by LC/MS-MS; NO production was quantified with an amperometric sensor implanted in the contralateral hippocampus. Antinociceptive effect was monitored at selected time points during and following infusion by electrical stimulation vocalization. The data were fit with a pharmacokinetic/pharmacodynamic model to obtain parameters governing morphine disposition, stimulation of NO production, antinociception, and antinociceptive tolerance development. An additional three groups of rats were pretreated with l-arginine, the NO precursor (100, 300, or 500 mg/kg/h for 8 h), to elevate NO concentrations prior to morphine infusion. Morphine administration resulted in a dose-dependent increase in NO production; the time course of altered NO production coincided with the development of antinociceptive tolerance. l-arginine pretreatment initially enhanced morphine-induced analgesia early in the morphine infusion. However, this NO-associated increase in opioid response dissipated rapidly due to a dominant NO-induced loss of antinociception. Pharmacodynamic modeling suggested that this latter effect was consistent with a hyperalgesic response. These data define a strong, time-dependent relationship between morphine-induced stimulation of NO production and tolerance development, identify specific NO-induced alterations in nociceptive processing after morphine administration, and indicate that NO is a key mediator of antinociceptive tolerance development.
Heinzen
Erin L
EL
Division of Drug Delivery and Disposition, School of Pharmacy, University of North Carolina, CB No. 7360, Kerr Hall, Chapel Hill, NC 27599-7360, USA.
Pollack
Gary M
GM
D000700:Analgesics / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology*; D000704:Analysis of Variance; D000818:Animals; D019540:Area Under Curve; D001120:Arginine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004361:Drug Tolerance; D004558:Electric Stimulation / Q000379:methods; D004563:Electrochemistry / Q000379:methods; D008401:Gas Chromatography-Mass Spectrometry / Q000379:methods; D006624:Hippocampus / Q000187:drug effects / Q000201:enzymology; D008297:Male; D017551:Microdialysis / Q000379:methods; D008954:Models, Biological; D009020:Morphine / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology*; D009021:Morphine Dependence / Q000378:metabolism*; D009474:Neurons / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism*; D010147:Pain Measurement / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors; D014018:Tissue Distribution / Q000187:drug effects
D000700:Analgesics; D009569:Nitric Oxide; D009020:Morphine; D001120:Arginine